Study to evaluate methods that assess the effect of AZD4017 in adipose tissue

Study identifier:D2060M00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, single-blind, placebo-controlled, single-centre, Phase I study in abdominally obese healthy volunteers to evaluate methods to assess 11-βHSD1 activity in adipose tissue and related downstream biomarkers after single and repeated oral doses of AZD4017 for 10 days

Medical condition

obesity

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD4017, Placebo

Sex

Male

Actual Enrollment

15

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Mar 2010
Primary Completion Date: 01 May 2010
Study Completion Date: 01 May 2010

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Other

Verification:

Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria